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Cannabis Use Disorder and Surgery: A Budding Problem?
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For many anesthesiologists, discussions with patients and colleagues about cannabis have 
been occurring more often. Cannabis, also called marijuana, contains various components 
that activate the endocannabinoid system including delta-9-tetrahydrocannabinol (THC) and 
cannabidiol (CBD), both of which have been topics of national discourse.1,2 The need for 
better evidence regarding the effects of cannabis and its various cannabinoid and non-
cannabinoid components that impact the health of patients is especially heightened as 
cannabis is increasingly viewed by patients as an alternative to opioids. One question 
relevant to the anesthesiology community is whether patients who have a diagnosis of active 
cannabis use disorder have an increased risk of negative outcomes after surgery. Here, it is 
important to differentiate use of cannabis from cannabis use disorder, in which patients have 
problems from cannabis use that lead to “significant impairment or distress” such as 
cravings, tolerance, or withdrawal.3
In this issue of ANESTHESIOLOGY, Goel and colleagues present results from a 
retrospective study to test the hypothesis of whether a diagnosis of active cannabis use 
disorder increases the risk of complications and other negative outcomes prior to discharge 
from the hospital after surgery.4 Examining a nationally representative sample, the authors 
report that a diagnosis of active cannabis use disorder did not result in a worse outcome as 
measured by the primary outcome of a composite endpoint including in-hospital 
postoperative myocardial infarction, stroke, sepsis, deep vein thrombosis, pulmonary 
embolus, acute kidney injury requiring dialysis, respiratory failure, and in-hospital mortality. 
This observation is important because this study represents a nationally representative 
sample of adults undergoing elective surgery, which is the largest investigation of its kind to 
date. This analysis also importantly controls for conditions known or presumed to influence 
cannabis use, such as the presence of other substance use disorders and certain types of 
mental health conditions.
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The authors also evaluated several secondary outcomes, including hospital length of stay, 
total hospital costs, and the individual components of the composite endpoint. One of those, 
acute myocardial infarction, was associated with cannabis use disorder, and was greater in 
absolute terms (0.3% vs 0.7%). To assess the risk of worse outcomes after surgery among 
people with cannabis use disorder alone versus co-morbid cannabis and other substance use 
disorders, the authors performed a separate match to restrict the study population to those 
who had no other diagnoses of substance use disorders besides cannabis and found similar 
results. While this finding regarding the secondary outcome is interesting, the appearance of 
no difference in the compositive measure of multiple endpoints should be considered in the 
context of certain limitations, many of which the authors acknowledge. One limitation of 
many analyses that use administrative data to analyze substance use disorder is that the true 
incidence of substance use disorder such as cannabis use disorder is likely not accurately 
captured in claims. The authors appropriately recognize that the sensitivity for a diagnosis of 
active cannabis use disorder may be suspected to be low, given the likelihood that claims 
lack an active diagnosis for some population of patients who actually qualify for the 
diagnosis. If true, this could bias results toward the null. Another point to consider is that the 
dataset analyzed in this study does not capture additional relevant risk factors prior to 
surgery. Besides chronic use of medications such as opioids, a more nuanced understanding 
of mental health diagnoses prior to surgery would help to reduce the possibility of bias.
Goel and colleagues also describe a more than three-fold escalation in the rate of active 
cannabis use disorder among surgical patients from 2006 to 2015. While cannabis use 
remains illegal under federal law, cannabis use has become more common in the setting of 
two different types of state laws. First, state legislatures have passed medical cannabis laws, 
which authorize the use of cannabis for certain qualifying health conditions. As of 2019, 33 
states and the District of Columbia have enacted comprehensive medical cannabis laws, 
which vary markedly in regard to the scope of health conditions covered.5 Thirteen 
additional states have enacted laws allowing access to strains of cannabis that are low in 
delta-9-tetrahydrocannabinol and high in cannabidiol, principally for treatment of intractable 
seizure disorders. A smaller contingent—11 states and the District of Columbia—has 
legislated the recreational use of cannabis, making it widely accessible to adults aged 21+ 
irrespective of the presence of medical conditions. Based on a recent nationwide survey, 
more than 43 million persons (16%) reported cannabis use last year, and during this same 
timeframe more than 4.4 million persons (1.6%) reported cannabis use disorder.6
It is reasonable to anticipate that increasing availability and exposure of patients to cannabis 
may result in more patients reporting cannabis use disorder before surgery if their 
anesthesiologists and anesthesiology care team ask about cannabis. Questions about 
cannabis use may be included with related topics such as tobacco and other substance use. 
The perioperative period provides an important opportunity to counsel patients about 
behaviors that impact patient health during and after the time of surgery. Recommendations 
for patients to stop using tobacco products prior to surgery, which derive from a firm 
foundation of evidence, may provide a useful model for investigators to pursue when 
studying methods to reduce active cannabis use before surgery.7 For example, while tobacco 
cessation prior to surgery was found to be beneficial, additional study revealed that stopping 
smoking on the day before surgery might be worse than not doing so. Altogether, it is 
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appropriate to recognize that the data on outcomes associated with cannabis use and surgery 
are nascent at best, and additional evidence will refine our perspective how cannabis may 
result in health risks in the perioperative period. In conclusion, while a firm consensus does 
not yet exist on whether patients who have cannabis use disorder have a higher risk of 
negative outcomes related to surgery, this study suggests the possibility of increased 
perioperative risk of myocardial infarction. The overall uncertainty about risks in the 
perioperative period may be appropriate for anesthesiologists and surgeons to discuss with 
patients who actively use cannabis.
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